Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that two injections of platelet-rich plasma were safe but no more effective than placebo in treating mild to moderate erectile dysfunction.

This retrospective pharmacovigilance study identified 34 drugs, including finasteride and dutasteride, that may be associated with sexual dysfunction, with a higher risk observed in males aged 31-45.

This article discusses the management of male lower urinary tract symptoms (LUTS) and presents randomized placebo-controlled study results on finasteride use, but it reports no new clinical findings.

This study found that the herbal combination PRO 160/120 significantly improved nocturnal voiding frequency in patients with moderate-to-severe LUTS/BPH compared to placebo, with similar effectiveness to tamsulosin and finasteride.

The researchers reported an increased risk of malignant melanoma and nonmelanoma skin cancers with the use of angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors, and thiazides in a large patient study.

This study found that finasteride significantly inhibits the metabolism of tirilazad to its active metabolites without greatly affecting tirilazad's overall clearance.

This review highlights that sexual dysfunction associated with 5-alpha-reductase inhibitors is recognized in clinical literature, with erectile dysfunction being the most common adverse effect, followed by ejaculatory dysfunction and decreased libido.

This study found a positive association between erectile dysfunction and the functionality of the marital subsystem in patients with benign prostatic hyperplasia treated with tamsulosin and finasteride.

Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This study classified dutasteride, fesoterodine, and finasteride as beneficial for older or frail elderly patients, while suggesting caution or avoidance of α-blockers and antimuscarinics in this group.

This study found that dutasteride may reduce the likelihood of hospitalization for BPH-related surgery and newly detected prostate cancer, compared to finasteride, and suggests a budgetary benefit.

This study found that independent pharmacies in the St. Louis metropolitan area offer significantly lower prices for certain generic urologic medications compared to chain pharmacies, regardless of geography or zip code income.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

This study found that finasteride may reduce inappropriate sexual behaviors in geriatric patients with vascular dementia and benign prostate hyperplasia without serious side effects, though some patients required additional medications.

This review discusses various treatment options for lower urinary tract symptoms in men, including behavioral, pharmacologic, and surgical interventions, and reports no new clinical results; the authors emphasize first-line therapy with behavioral and pharmacologic approaches.

This study developed and validated a sensitive and rapid method to simultaneously measure alfuzosin and dutasteride in human plasma, enabling high-throughput analysis for pharmacokinetic and bioequivalence studies.

This study found that long-term administration of tamsulosin hydrochloride 0.2 mg is effective, safe, and well-tolerated for improving symptoms and quality of life in patients with LUTS of BPH.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.